Last update 27 Dec 2024

Norfloxacin

Last update 27 Dec 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, NFLX

+ [28]

Target

Bacterial DNA gyrase

Mechanism

Bacterial DNA gyrase inhibitors

Therapeutic Areas

Infectious DiseasesDigestive System DisordersEye Diseases+ [2]

Active Indication

Dysentery, BacillaryGastrointestinal infectionTurista+ [12]

Inactive Indication

Cystitis

Originator Organization

KYORIN Pharmaceutical Co., Ltd.

Active Organization

KYORIN Pharmaceutical Co., Ltd.Central Pharmaceutical JSC No. 3

Arrotex Pharmaceuticals Pty Ltd.Startup

+ [1]

Inactive Organization

Merck Research Laboratories Massachusetts LLC

Eurofarma Laboratórios SA

Drug Highest PhaseApproved

First Approval Date

JP (15 Feb 1984),

Infectious Diseases

Regulation-

Structure

Molecular FormulaC16H18FN3O3

InChIKeyOGJPXUAPXNRGGI-UHFFFAOYSA-N

CAS Registry70458-96-7

Clinical Trials associated with Norfloxacin

CTR20241157 / CompletedNot Applicable

诺氟沙星胶囊（0.1g）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence study of norfloxacin capsules (0.1 g) in Chinese healthy volunteers under fasting conditions

主要研究目的：按有关生物等效性试验的规定，选择杏林制药株式会社为持证商的诺氟沙星片（商品名：BACCIDAL®，规格：100mg/片）为参比制剂，对哈药集团制药六厂生产、哈药集团制药总厂提供的受试制剂诺氟沙星胶囊（规格：0.1g/粒）进行空腹给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评估两种制剂在空腹给药条件下的生物等效性。次要研究目的：观察健康志愿受试者口服受试制剂诺氟沙星胶囊（规格：0.1g/粒）和参比制剂诺氟沙星片（商品名：BACCIDAL®，规格：100mg/片）的安全性。

[Translation]

Main research purpose: According to the relevant provisions of bioequivalence test, the norfloxacin tablets (trade name: BACCIDAL®, specification: 100mg/tablet) of which Xinglin Pharmaceutical Co., Ltd. is the licensee was selected as the reference preparation, and the test preparation norfloxacin capsules (specification: 0.1g/tablet) produced by Harbin Pharmaceutical Group Pharmaceutical Factory No. 6 and provided by Harbin Pharmaceutical Group Pharmaceutical Factory were tested for human bioequivalence under fasting administration. The absorption rate and degree of the drug in the test preparation were compared with those of the reference preparation to see if they were within an acceptable range, and the bioequivalence of the two preparations under fasting administration conditions was evaluated. Secondary research purpose: To observe the safety of oral administration of the test preparation norfloxacin capsules (specification: 0.1g/tablet) and the reference preparation norfloxacin tablets (trade name: BACCIDAL®, specification: 100mg/tablet) by healthy volunteers.

Start Date15 Apr 2024

Sponsor / Collaborator

Harbin Pharmaceutical Group Co. Ltd. General Pharm Factory

CTR20240282 / CompletedNot Applicable

诺氟沙星胶囊在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、双交叉空腹生物等效性试验研究方案

[Translation] Study plan for a single-center, randomized, open-label, two-formulation, single-dose, two-period, double-crossover fasting bioequivalence trial of norfloxacin capsules in healthy subjects

主要目的：以药代动力学参数作为主要终点评价指标，比较在空腹状态下口服受试制剂诺氟沙星胶囊（规格：0.1g，持证商：广东恒健制药有限公司）与参比制剂诺氟沙星片（规格：0.1g，持证商：杏林制药株式会社，商品名：BACCIDAL®）后在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：观察受试制剂诺氟沙星胶囊和参比制剂诺氟沙星片在健康受试者中的安全性。

[Translation]

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, compare the pharmacokinetic behavior of the test preparation norfloxacin capsule (specification: 0.1g, license holder: Guangdong Hengjian Pharmaceutical Co., Ltd.) and the reference preparation norfloxacin tablet (specification: 0.1g, license holder: Xinglin Pharmaceutical Co., Ltd., trade name: BACCIDAL®) in healthy subjects after oral administration in the fasting state, and evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation norfloxacin capsule and the reference preparation norfloxacin tablet in healthy subjects.

Start Date03 Mar 2024

Sponsor / Collaborator

Jiangmen Hengjian Pharmaceutical Co. Ltd.

CTR20230089 / CompletedNot Applicable

诺氟沙星胶囊在健康受试者中空腹状态下的单中心、随机、开放、两制剂、单剂量、双周期、两序列、双交叉生物等效性试验研究方案

[Translation] A single-center, randomized, open-label, two-formulation, single-dose, two-period, two-sequence, double-crossover bioequivalence study protocol for norfloxacin capsules in healthy subjects under fasting condition

主要目的：以药代动力学参数作为主要终点评价指标，比较在空腹状态下口服受试制剂诺氟沙星胶囊（生产厂家：武汉同济现代医药科技股份有限公司）与参比制剂诺氟沙星片（持证商：杏林制药株式会社，商品名：BACCIDAL®）后在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：观察受试制剂诺氟沙星胶囊和参比制剂诺氟沙星片在健康受试者中的安全性。

[Translation]

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, compare the pharmacokinetic behavior of the test preparation norfloxacin capsules (manufacturer: Wuhan Tongji Modern Pharmaceutical Technology Co., Ltd.) and the reference preparation norfloxacin tablets (licensed manufacturer: Xinglin Pharmaceutical Co., Ltd., trade name: BACCIDAL®) in healthy subjects after oral administration in the fasting state, and evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation norfloxacin capsules and the reference preparation norfloxacin tablets in healthy subjects.

Start Date22 Feb 2023

Sponsor / Collaborator

Wuhan Tongji Modern Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Norfloxacin

100 Translational Medicine associated with Norfloxacin

100 Patents (Medical) associated with Norfloxacin

5,647

Literatures (Medical) associated with Norfloxacin

01 Mar 2025·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Electro-activated peroxymonosulfate based on hollow cubic skeleton nanoflower cathode catalyst MoSe2/cubic nanocage (CNC) for enhanced degradation of norfloxacin: Performance, mechanism, degradation pathways and toxicity

Article

Author: Fan, Zhirui ; Song, Peipei ; Liu, Jin

Recently, antibiotic wastewater pollution has become increasingly serious. In this study, a novel hollow cubic framework self-supported nanoflower-like cathode catalyst (MoSe₂/CNC) based on Co Fe prussian blue analogues (CoFePBA)-derived cubic nanocage (CNC) loaded with MoSe₂ was successfully prepared and utilized in an electro-activated peroxymonosulfate (PMS) system for norfloxacin (NOR) degradation. Benefit from the combined structures of MoSe₂, MoC, and Co/FeNC, the electrocatalytic activity and specific surface area were greatly improved. The effects of catalyst dosage and ratio, current, PMS concentration, electrolyte type, pH, as well as initial concentration were comprehensively investigated. Under the optimal conditions, NOR and TOC removal reached 92.70% and 82.17%, respectively, which was superior to the previous studies. Additionally, ·O₂^- was proved to be the primary reactive species for NOR degradation.·Based on density functional theory (DFT) and intermediates analysis, NOR underwent substitution and ring-opening reactions in the piperazine ring, substitution of fluoride ions, and cleavage of the carboxyl group and tetrahydropyridine ring, ultimately converting into water, carbon dioxide, and inorganic ions. Moreover, toxicity assessment and seed germination experiments demonstrated that the toxicity of NOR and intermediates were strongly decreased by electro-activated PMS system based on MoSe₂/CNC cathode. Overall, this study not only contributes to the evolution of efficient and sustainable wastewater purification technology, but also provides valuable insights into the degradation of antibiotic wastewater.

01 Mar 2025·JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Evaluation of inhibition and eradication of bacterial biofilm by solasodin

Article

Author: da Silva, Ana Raquel Pereira ; de Alencar, Maria Anésia Sousa ; Coutinho, Henrique Douglas Melo ; Andrade-Pinheiro, Jacqueline Cosmo ; Barbosa-Filho, José Maria ; Costa, Maria do Socorro ; Paulo, Cícera Laura Roque ; de Freitas, Thiago Sampaio ; Araújo, Nara Juliana Santos

Biofilms are complex microbial structures that have a significant impact on human health, industry and the environment. These complex structures represent one of the main mechanisms of microbial resistance, and their development constitutes a serious health problem. Therefore, the aim of this study was to verify the potential for inhibition and eradication of bacterial biofilm by salosodine, which is a steroidal alkaloid sapogenin found in plants of the Solanum genus. The antibiotics gentamicin, norfloxacin, ampicillin and the antiseptic agent chlorhexidine gluconate were used as positive controls to compare the results. Solasodin showed significant results in inhibiting the formation of Enterococcus faecalis and Staphylococcus aureus biofilms at the two concentrations tested. And when comparing the effect of solasodine for the two concentrations and the effect of the antibiotic gentamicin, it was found that sapogenin showed a better percentage in inhibiting E. faecalis biofilm formation. And against Pseudomonas aeruginosa, solasodine only inhibited biofilm formation at the highest concentration compared to the control. In the biofilm eradication results, solasodine showed a significant reduction in the biomass of the S. aureus biofilm, and when compared with the percentage reduction of the antibiotics, solasodine showed a relevant result for both concentrations. Only at the lowest concentration did solasodine show a reduction in P. aeruginosa biofilm biomass, a reduction close to that of chlorhexidine gluconate. In terms of activity, solasodine has been shown to have the potential to inhibit biofilm formation. However, further tests are needed to investigate the mechanisms of action of this sapogenin on the bacterial biofilms tested.

01 Mar 2025·JOURNAL OF COLLOID AND INTERFACE SCIENCE

A new molecularly imprinted nanocatalytic probe for RRS determination of trace enrofloxacin based on covalent organic framework polymer

Article

Author: Wen, Guiqing ; Li, Jingjing ; Jiang, Zhiliang ; Liang, Aihui

A new nanopalladium surface molecularly imprinted covalent organic framework (MICOF) catalytic probe (Pd@TpPa) for enrofloxacin (ENR) was synthesized by molecular imprinting technology, using 1,3,5-triformylphloroglucinol (Tp) and p-phenylenediamine (Pa) as monomers, ENR as the template molecule, and palladium nanoparticles (PdNP) as the core of nanocatalytic probe. This nanoprobe not only specifically recognizes ENR but also catalyzes the cupric tartrate-glucose (GL) indicator reaction. The amino groups in TpPa replace the tartrate ions, forming a new complex with Cu²⁺. This new complex enhances the efficiency of GL oxidation reaction. The generated Cu₂O nanoparticles exhibit strong resonance Rayleigh scattering (RRS) and absorption (Abs) peaks at 370 nm and 500 nm, respectively. The catalytic and analytical performances of metal nanoparticles including Pd, Pt, Au and Ag were studied. It was found that Pd@TpPa_ENR exhibited the best performance. The RRS response was linear to ENR concentration in the range of 0.01-1.5 nM, with a detection limit of 0.008 nM ENR. The method was applied to analyze river water samples, yielding recoveries of 96.9-106.6 % and precision between 2.33-8.49 %. This nanocatalytic probe-RRS analysis platform is simple, sensitive, selective, and versatile, making it applicable for the determination of norfloxacin (NOR), ofloxacin, pefloxacin, fleroxacin, and ciprofloxacin, with linear ranges of 0.02-6.0 nM, 0.04-6.0 nM, 0.04-6.0 nM, 0.1-15 nM, and 0.1-15 nM, respectively.

News (Medical) associated with Norfloxacin

09 Feb 2021

·www.globenewswire.com

Global Urinary Tract Infection Treatment Markets, 2020-2027 - Market for Penicillin and Combination Drugs Segment to Grow at Highest Rate

Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Urinary Tract Infection Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class, Indication, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering. Market for Penicillin and Combination Drugs Segment to Grow at Highest CAGR during 2020-2027. The market is expected to reach US$ 11,614.32 million by 2027 from US$ 9,106.40 million in 2019; it is estimated to grow at a CAGR of 3.2% from 2020 to 2027. The growth of the market is attributed to the growing prevalence of urinary tract infections, aging population, and emerging computing technologies for urine diagnostics. However, the lack of product awareness in emerging countries and effects associated with medication obstruct the growth of the market to a certain extent. Based on drug class, the quinolones segment held the largest share of the market in 2019; however, the penicillin and combination segment is anticipated to register the highest CAGR of 4.5% in the market during the forecast period. The future growth of the market for quinolones is mainly ascribed to the fact that it is most commonly prescribed by physicians. Ciprofloxacin, levofloxacin, and enoxacin are among the most widely used drugs for treatment. R& D in UTI treatment is expected to offer lucrative growth opportunities to the players in the global urinary tract infection treatment market. For instance, in July 2018, Lupin received approval from the US Food and Drug Administration (FDA) for generic Nitrofurantoin capsules. It is a generic version of Macrodantin offered by Alvogen Malta Operations Ltd. It is used to treat UTI caused by Staphylococcus aureus, enterococci, etc. Further, in February 2020, a France-based pharmaceutical company announced Exblifep, a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and cefepime. i.e., the fourth-generation cephalosporin, which achieved primary endpoints in a clinical trial for complicated UTIs. Moreover, in July 2019, Healthy.io, a smartphone camera-based solutions developer, announced an agreement with Walgreens Boots Alliance, Inc. placing Healthy.io's Dip UTI test kits in boots pharmacies throughout the UK. Additionally, in May 2020, Spero Therapeutics, Inc. announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, of tebipenem HBr to treat complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In July 2019, the US FDA approved Recarbrio drug to treat cUTI and complicated intra-abdominal infection in adults. In June 2018, Achaogen, Inc. received the US FDA approval for ZEMDRI to treat cUTIs in adults. In November 2018, Allergan, announced the launch of the FDA accepted supplemental drug AVYCAZ to treat cUTIs and complicated intra-abdominal infections patients between the age group of 3 months to 18 years. Applying such strategic measures can be lucrative for the urinary tract infection treatment market during the forecast period. Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., ALLERGAN, Pfizer Inc., Cipla Ltd, F. Hoffmann-La Roche Ltd, Shionogi Inc., Amway, and DuPont Nutrition & Biosciences are among the leading companies in the urinary tract infection treatment market. Key Topics Covered: 1. Introduction 2. Urinary Tract Infection Treatment Market - Key Takeaways 3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research 4. Urinary Tract Infection Treatment Market - Market Landscape 4.1 Overview 4.2 PEST Analysis 4.3 Expert Opinion 5. Urinary Tract Infection Treatment Market - Key Market Dynamics 5.1 Market Drivers 5.1.1 Growing Urinary Tract Infections 5.1.2 Aging Population 5.1.3 Emerging Computing Technologies for Urine Diagnostics 5.2 Market Restraints 5.2.1 Associated Effects of Medication 5.3 Market Opportunities 5.3.1 R&D in UTI Treatment 5.4 Future Trends 5.4.1 Nutritional Supplement in UTI 6. Urinary Tract Infection Treatment Market - Global Analysis 6.1 Global Urinary Tract Infection Treatment Market Revenue Forecast and Analysis 6.2 Global Urinary Tract Infection Treatment Market, By Geography - Forecast and Analysis 6.3 Market Positioning of Key Players 7. Urinary Tract Infection Treatment Market Analysis - By Drug Class 7.1 Overview 7.2 Urinary Tract Infection Treatment Market Revenue Share, by Drug Class (2019 and 2027) 7.3 Penicillin and Combinations 7.3.1 Overview 7.3.2 Penicillin and Combinations: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million) 7.3.3 Amoxicillin 7.3.4 Amoxicillin and Clavulanate Potassium 7.4 Quinolones 7.4.1 Overview 7.4.2 Quinolones: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million) 7.4.3 Ciprofloxaxin 7.4.4 Levofloxaxin 7.4.5 Nalidixic Acid 7.4.6 Norfloxacin 7.4.7 Others 7.5 Cephalosporin 7.6 Aminoglycoside Antibiotics 7.7 Sulphonamides 7.8 Nutritional Supplements 7.8.1 Overview 7.8.2 Nutritional Supplements: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million) 7.8.3 Cranberry Supplements 7.8.4 D-Mannose 7.8.5 Probiotics 7.8.6 Vitamin-C 8. Urinary Tract Infection Treatment Market Analysis - By Indication 8.1 Overview 8.2 Urinary Tract Infection Treatment Market Revenue Share, by Indication (2019 and 2027) 8.3 Complicated Urinary Tract Infections 8.4 Uncomplicated Urinary Tract Infections 9. Urinary Tract Infection Treatment Market Analysis - By Distribution Channel 9.1 Overview 9.2 Urinary Tract Infection Treatment Market Revenue Share, by Distribution Channel (2019 and 2027) 9.3 Hospital Pharmacies 9.4 Retail Pharmacies & Drug Stores 9.5 Gynaecology and Urology Clinics 9.6 Online Drug Stores 10. Urinary Tract Infection Treatment Market - Geographic Analysis 11. Impact of COVID-19 Pandemic on Global Urinary Tract Infection Treatment Market 12. Urinary Tract Infection Treatment Market-Industry Landscape Companies Mentioned Teva Pharmaceutical Industries Ltd Sun Pharmaceutical Industries Ltd Mylan N.V. ALLERGAN Pfizer Inc. Cipla Ltd F. Hoffmann-La Roche Ltd Shionogi Inc. Amway DuPont Nutrition & Biosciences For more information about this report visit CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Collaborate

100 Deals associated with Norfloxacin

External Link

KEGG	Wiki	ATC	Drug Bank
D00210	Norfloxacin	J01MA06 S01AE02	DB01059

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dysentery, Bacillary	AU	Arrotex Pharmaceuticals Pty Ltd.Startup	13 Nov 2001
Gastrointestinal infection	AU	Arrotex Pharmaceuticals Pty Ltd.Startup	13 Nov 2001
Turista	AU	Arrotex Pharmaceuticals Pty Ltd.Startup	13 Nov 2001
Corneal Ulcer	JP	KYORIN Pharmaceutical Co., Ltd.	24 Nov 1992
Blepharitis	JP	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Blepharitis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Conjunctivitis	JP	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Dacryocystitis	JP	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Dacryocystitis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Hordeolum	JP	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Hordeolum	JP	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Keratitis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Gonorrhea	CN	Central Pharmaceutical JSC No. 3	01 Jan 1986
Prostatitis	CN	Central Pharmaceutical JSC No. 3	01 Jan 1986
Salmonella Infections	CN	Central Pharmaceutical JSC No. 3	01 Jan 1986
Typhoid Fever	CN	Central Pharmaceutical JSC No. 3	01 Jan 1986
Urinary Tract Infections	CN	Central Pharmaceutical JSC No. 3	01 Jan 1986
Infectious Diseases	JP	KYORIN Pharmaceutical Co., Ltd.	15 Feb 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cystitis	Phase 3	-	Eurofarma Laboratórios SA	01 Oct 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03584724 (CTgov)	Early Phase 1	Uveitis	49	Norflo Oro (Norflo Oro)	lubtjelikj(yraymuxsgm) = ugsoyaokxs ngifooumzh (shdpgwoufl, owihrareny - nsndqpgeem) View more	-	28 Mar 2022
				Placebo for Norflo Oro (Placebo for Norflo Oro)	lubtjelikj(yraymuxsgm) = qwiewzwlue ngifooumzh (shdpgwoufl, nevfnxican - pjtlrubwxl) View more
EASL2020	Not Applicable	Spontaneous bacterial peritonitis	1,626	Norfloxacin	pemieejzje(tbjgksjaez) = ubobypvaag dxxkdkkzbv (qiefgaeljo ) View more	Negative	27 Aug 2020
				Placebo	-
NCT01037959 (Pubmed \| Gastroenterology)	Phase 3	Fibrosis	291	Norfloxacin 400 mg	qlhzitmseo(mqhsncysqi) = zaoypbhssk ahkcaicjdx (gayhxjoyhb )	-	01 Dec 2018
				Placebo	qlhzitmseo(mqhsncysqi) = ypzwmqxhwr ahkcaicjdx (gayhxjoyhb )
NCT00362752 (Pubmed \| Clin Gastroenterol Hepatol)	Phase 2	Hepatopulmonary Syndrome	9	Placebo	xkpnguflhb(kotnkinmtc) = lfrncvutyh fqudzumekr (vhqrjwhhwc )	-	01 Dec 2010
AAAAI2010	Not Applicable	Hypersensitivity	-	Quinolones (Anaphylaxis patients)	iovguoanpf(vchbpacnia) = vysxvawztb ammmiffhjj (rlerzoyjgv )	Positive	01 Feb 2010
				Quinolones (Urticaria patients)	iovguoanpf(vchbpacnia) = duphwkdmfu ammmiffhjj (rlerzoyjgv )
ARVO2002	Not Applicable	-	-	Levofloxacin 0.5%	dgcffmrsri(uojqpttysn) = clucryuxju ekfpqdtjhx (emoehygipx, 3.53)	-	01 Dec 2002
				Norfloxacin 0.3%	dgcffmrsri(uojqpttysn) = lmnitckdgw ekfpqdtjhx (emoehygipx, 1.18)
NCT04159870 (Pubmed \| Gastroenterology)	Phase 3	Gastrointestinal Hemorrhage	119	Norfloxacin	ebftsqzujk(bobthbqzpf) = vtrukxzhgr swouckvzmz (cnzkkcuxas ) View more	-	01 Oct 1992
				Norfloxacin (Control)	khrmsmnaau(vgwccdiovv) = zgjyhuzxqm haoqlyudpd (mkufdggdtk ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis